209 related articles for article (PubMed ID: 19464324)
61. [The use of atypical antipsychotics in the long-term care of schizophrenia].
Limosin F
Encephale; 2006 Dec; 32 Pt 3():S1065-71. PubMed ID: 17356501
[No Abstract] [Full Text] [Related]
62. Effects of antipsychotic drugs on operant responding after acute and repeated administration.
Varvel SA; Vann RE; Wise LE; Philibin SD; Porter JH
Psychopharmacology (Berl); 2002 Mar; 160(2):182-91. PubMed ID: 11875636
[TBL] [Abstract][Full Text] [Related]
63. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
Sacchetti E; Valsecchi P
Int Clin Psychopharmacol; 2003 Nov; 18(6):357-9. PubMed ID: 14571157
[TBL] [Abstract][Full Text] [Related]
64. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
[TBL] [Abstract][Full Text] [Related]
65. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
66. [The use of antipsychotics in patients with dementia].
Forlenza OV; Cretaz E; Diniz BS
Braz J Psychiatry; 2008 Sep; 30(3):265-70. PubMed ID: 18833428
[TBL] [Abstract][Full Text] [Related]
67. Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats.
Ahlqvist J; Isacson R; Wahlestedt C; Salmi P
Eur Neuropsychopharmacol; 2003 May; 13(3):177-82. PubMed ID: 12729943
[TBL] [Abstract][Full Text] [Related]
68. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Schmidt AW; Lebel LA; Howard HR; Zorn SH
Eur J Pharmacol; 2001 Aug; 425(3):197-201. PubMed ID: 11513838
[TBL] [Abstract][Full Text] [Related]
69. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
Assié MB; Bardin L; Auclair A; Consul-Denjean N; Sautel F; Depoortère R; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):241-50. PubMed ID: 17453175
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.
Bricker B; Sampson D; Ablordeppey SY
Pharmacol Biochem Behav; 2014 May; 120():109-16. PubMed ID: 24565832
[TBL] [Abstract][Full Text] [Related]
71. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
Terranova JP; Chabot C; Barnouin MC; Perrault G; Depoortere R; Griebel G; Scatton B
Psychopharmacology (Berl); 2005 Aug; 181(1):134-44. PubMed ID: 15830220
[TBL] [Abstract][Full Text] [Related]
72. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Cohen D; Correll CU
J Clin Psychiatry; 2009 May; 70(5):765-6. PubMed ID: 19552870
[No Abstract] [Full Text] [Related]
73. Atypical antipsychotics and diabetes mellitus.
Schwenkreis P; Assion HJ
World J Biol Psychiatry; 2004 Apr; 5(2):73-82. PubMed ID: 15179666
[TBL] [Abstract][Full Text] [Related]
74. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
Prinssen EP; Kleven MS; Koek W
Eur J Pharmacol; 1998 Sep; 356(2-3):189-92. PubMed ID: 9774248
[TBL] [Abstract][Full Text] [Related]
75. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.
Newman-Tancredi A; Kleven MS
Psychopharmacology (Berl); 2011 Aug; 216(4):451-73. PubMed ID: 21394633
[TBL] [Abstract][Full Text] [Related]
76. N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.
Birch AM; Bradley PA; Gill JC; Kerrigan F; Needham PL
J Med Chem; 1999 Aug; 42(17):3342-55. PubMed ID: 10464021
[TBL] [Abstract][Full Text] [Related]
77. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Rasmussen K; Hsu MA; Noone S; Johnson BG; Thompson LK; Hemrick-Luecke SK
Schizophr Bull; 2007 Nov; 33(6):1291-7. PubMed ID: 17660489
[TBL] [Abstract][Full Text] [Related]
78. Neutropenia associated with quetiapine, olanzapine, and aripiprazole.
Lander M; Bastiampillai T
Aust N Z J Psychiatry; 2011 Jan; 45(1):89. PubMed ID: 21058927
[No Abstract] [Full Text] [Related]
79. Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine.
Goudie AJ; Smith JA; Millan MJ
Psychopharmacology (Berl); 2004 Jan; 171(2):212-22. PubMed ID: 14691616
[TBL] [Abstract][Full Text] [Related]
80. A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania.
Jones RM; Thompson C; Bitter I
Eur Psychiatry; 2006 Jan; 21(1):1-9. PubMed ID: 16487905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
